Paolo Calabresi

List of Publications by Year
in descending order

602	36,936	2101 100	6300 158
papers	citations	h-index	g-index

607	607	607	29723
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Loss of bidirectional striatal synaptic plasticity in L-DOPAâ€“induced dyskinesia. Nature Neuroscience, 2003, 6, 501-506.	14.8	791
2	Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences, 2007, 30, 211-219.	8.6	707
3	Long-term synaptic depression in the striatum: physiological and pharmacological characterization. Journal of Neuroscience, 1992, 12, 4224-4233.	3.6	639
4	Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 870-881.	1.9	623
5	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	3.9	608
6	Direct and indirect pathways of basal ganglia: a critical reappraisal. Nature Neuroscience, 2014, 17, 1022-1030.	14.8	598
7	Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1. Neuron, 2005, 45, 489-496.	8.1	485
8	The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends in Neurosciences, 1996, 19, 19-24.	8.6	420
9	Acetylcholine-mediated modulation of striatal function. Trends in Neurosciences, 2000, 23, 120-126.	8.6	400
10	CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586.	10.2	393
11	Longâ€term Potentiation in the Striatum is Unmasked by Removing the Voltageâ€dependent Magnesium Block of NMDA Receptor Channels. European Journal of Neuroscience, 1992, 4, 929-935.	2.6	380
12	Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity. Journal of Neuroscience, 2000, 20, 8443-8451.	3.6	337
13	Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurology, The, 2010, 9, 1106-1117.	10.2	329
14	Dopaminergic control of synaptic plasticity in the dorsal striatum. European Journal of Neuroscience, 2001, 13, 1071-1077.	2.6	319
15	Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission. Journal of Neuroscience, 2002, 22, 6900-6907.	3.6	303
16	Migraine and psychiatric comorbidity: a review of clinical findings. Journal of Headache and Pain, 2011, 12, 115-125.	6.0	301
17	Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience, 2001, 106, 579-587.	2.3	292
18	A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamineâ€“acetylcholine synaptic balance. Lancet Neurology, The, 2006, 5, 974-983.	10.2	289

#	Article	IF	Citations
19	Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors. Journal of Neuroscience, 1997, 17, 4536-4544.	3.6	279
20	Intracellular studies on the dopamine-induced firing inhibition of neostriatal neurons in vitro: Evidence for D1 receptor involvement. Neuroscience, 1987, 20, 757-771.	2.3	261
21	Synaptic transmission in the striatum: from plasticity to neurodegeneration. Progress in Neurobiology, 2000, 61, 231-265.	5.7	254
22	Nicotinic excitation of rat ventral tegmental neurones <i>in vitro</i> studied by intracellular recording. British Journal of Pharmacology, 1989, 98, 135-140.	5.4	253
23	Proinflammatory Cytokines, Adhesion Molecules, and Lymphocyte Integrin Expression in the Internal Jugular Blood of Migraine Patients Without Aura Assessed Ictally. Headache, 2006, 46, 200-207.	3.9	245
24	A Critical Interaction between NR2B and MAGUK in L-DOPA Induced Dyskinesia. Journal of Neuroscience, 2006, 26, 2914-2922.	3.6	243
25	Levodopaâ€induced dyskinesia in Parkinson disease: Current and evolving concepts. Annals of Neurology, 2018, 84, 797-811.	5.3	225
26	Cerebrospinal fluid lysosomal enzymes and alphaâ€synuclein in Parkinson's disease. Movement Disorders, 2014, 29, 1019-1027.	3.9	223
27	A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression. Journal of Neuroscience, 1999, 19, 2489-2499.	3.6	218
28	Unilateral Dopamine Denervation Blocks Corticostriatal LTP. Journal of Neurophysiology, 1999, 82, 3575-3579.	1.8	214
29	Does SARSâ€Covâ€2 invade the brain? Translational lessons from animal models. European Journal of Neurology, 2020, 27, 1764-1773.	3.3	214
30	Distinct Roles of D₁and D₅Dopamine Receptors in Motor Activity and Striatal Synaptic Plasticity. Journal of Neuroscience, 2003, 23, 8506-8512.	3.6	213
31	Post-receptor mechanisms underlying striatal long-term depression. Journal of Neuroscience, 1994, 14, 4871-4881.	3.6	209
32	Receptor Subtypes Involved in the Presynaptic and Postsynaptic Actions of Dopamine on Striatal Interneurons. Journal of Neuroscience, 2003, 23, 6245-6254.	3.6	209
33	Synaptic Dysfunction in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2012, 970, 553-572.	1.6	209
34	Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. British Journal of Pharmacology, 1997, 120, 1007-1014.	5.4	193
35	Properties of the Hyperpolarization-activated Cation Current Ihin Rat Midbrain Dopaminergic Neurons. European Journal of Neuroscience, 1995, 7, 462-469.	2.6	190
36	Correspondence. Neuroscience, 1997, 79, 323-327.	2.3	190

#	Article	IF	Citations
37	Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. Current Neuropharmacology, 2019, 17, 926-946.	2.9	190
38	Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. Neuroscience Letters, 1992, 142, 95-99.	2.1	186
39	Cerebrospinal fluid biomarkers in Parkinson disease. Nature Reviews Neurology, 2013, 9, 131-140.	10.1	177
40	Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends in Pharmacological Sciences, 2008, 29, 402-412.	8.7	172
41	New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet Neurology, The, 2013, 12, 811-821.	10.2	165
42	Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. Biological Psychiatry, 2008, 64, 850-855.	1.3	164
43	Cerebrospinal fluid Tau/Î±â€synuclein ratio in Parkinson's disease and degenerative dementias. Movement Disorders, 2011, 26, 1428-1435.	3.9	161
44	Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. European Journal of Neuroscience, 2000, 12, 1002-1012.	2.6	158
45	Abnormal Striatal GABA Transmission in the Mouse Model for the Fragile X Syndrome. Biological Psychiatry, 2008, 63, 963-973.	1.3	157
46	Diagnostic utility of cerebrospinal fluid Î±â€synuclein in Parkinson's disease: A systematic review and metaâ€analysis. Movement Disorders, 2017, 32, 1389-1400.	3.9	157
47	Levodopa in Parkinsonâ€™s Disease: Current Status and Future Developments. Current Neuropharmacology, 2018, 16, 1239-1252.	2.9	156
48	Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition. Journal of Neuroscience, 2010, 30, 14182-14193.	3.6	155
49	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiology of Disease, 2013, 52, 229-236.	4.4	155
50	Sex-Hormone-Related Events in Migrainous Females. A Clinical Comparative Study Between Migraine With Aura and Migraine Without Aura. Cephalalgia, 1995, 15, 140-144.	3.9	153
51	Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine. Journal of Neuroscience, 2001, 21, 5110-5120.	3.6	152
52	Focal status epilepticus as unique clinical feature of COVID-19: A case report. Seizure: the Journal of the British Epilepsy Association, 2020, 78, 109-112.	2.0	152
53	Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nature Reviews Neuroscience, 2018, 19, 599-609.	10.2	151
54	Electrophysiology of dopamine in normal and denervated striatal neurons. Trends in Neurosciences, 2000, 23, S57-S63.	8.6	145

#	Article	IF	Citations
55	Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. Journal of Neurochemistry, 2003, 85, 1018-1025.	3.9	145
56	Activation of D2-Like Dopamine Receptors Reduces Synaptic Inputs to Striatal Cholinergic Interneurons. Journal of Neuroscience, 2000, 20, RC69-RC69.	3.6	144
57	Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease. Movement Disorders, 2005, 20, 395-402.	3.9	141
58	Dopamine Excites Fast-Spiking Interneurons in the Striatum. Journal of Neurophysiology, 2002, 87, 2190-2194.	1.8	140
59	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D₂/A_{2A}Receptor Interaction in the Striatum: Implications for Parkinson's Disease. Journal of Neuroscience, 2011, 31, 1850-1862.	3.6	140
60	Discussion. Neuroscience, 1997, 78, 39-60.	2.3	139
61	Synaptic plasticity in the ischaemic brain. Lancet Neurology, The, 2003, 2, 622-629.	10.2	139
62	A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic Transmission. Neuropsychopharmacology, 2004, 29, 1488-1497.	5.4	139
63	Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Progress in Neurobiology, 2004, 74, 271-300.	5.7	139
64	Differential role of CSF alpha-synuclein species, tau, and AÃŽÂ²42 in Parkinson's Disease. Frontiers in Aging Neuroscience, 2014, 6, 53.	3.4	139
65	Medication-overuse headache: similarities with drug addiction. Trends in Pharmacological Sciences, 2005, 26, 62-68.	8.7	138
66	Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration. Frontiers in Neurology, 2018, 9, 295.	2.4	138
67	Abnormal Ca2+-Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism. Journal of Neuroscience, 2004, 24, 5283-5291.	3.6	136
68	Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice. Molecular Psychiatry, 2017, 22, 689-702.	7.9	134
69	Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. British Journal of Pharmacology, 1994, 113, 831-838.	5.4	133
70	Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. European Journal of Neuroscience, 1998, 10, 2887-2895.	2.6	133
71	Increased Levels of Neurotrophins Are Not Specific for Chronic Migraine: Evidence From Primary Fibromyalgia Syndrome. Journal of Pain, 2007, 8, 737-745.	1.4	132
72	Plasticity and repair in the post-ischemic brain. Neuropharmacology, 2008, 55, 353-362.	4.1	132

#	Article	IF	Citations
73	Cerebrospinal fluid Î²â€glucocerebrosidase activity is reduced in parkinson's disease patients. Movement Disorders, 2017, 32, 1423-1431.	3.9	132
74	Early synaptic dysfunction in Parkinson's disease: Insights from animal models. Movement Disorders, 2016, 31, 802-813.	3.9	127
75	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinsonâ€™s disease. Nature Communications, 2019, 10, 3945.	12.8	127
76	Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease. Annals of Neurology, 1998, 43, 586-597.	5.3	126
77	Decreased NR2B Subunit Synaptic Levels Cause Impaired Long-Term Potentiation But Not Long-Term Depression. Journal of Neuroscience, 2009, 29, 669-677.	3.6	126
78	Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Annals of Neurology, 2003, 53, 693-702.	5.3	125
79	Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain, 2011, 134, 375-387.	7.6	125
80	Lysosomal Dysfunction and Î±â€Synuclein Aggregation in Parkinson's Disease: Diagnostic Links. Movement Disorders, 2016, 31, 791-801.	3.9	125
81	Intracellular Calcium Increase in Epileptiform Activity: Modulation by Levetiracetam and Lamotrigine. Epilepsia, 2004, 45, 719-728.	5.1	124
82	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinsonâ€™s disease. Brain, 2012, 135, 1884-1899.	7.6	124
83	Synaptic and intrinsic control of membrane excitability of neostriatal neurons. I. An in vivo analysis. Journal of Neurophysiology, 1990, 63, 651-662.	1.8	122
84	Selective loss of glucocerebrosidase activity in sporadic Parkinsonâ€™s disease and dementia with Lewy bodies. Molecular Neurodegeneration, 2015, 10, 15.	10.8	120
85	Longitudinal changes in CSF alphaâ€synuclein species reflect Parkinson's disease progression. Movement Disorders, 2016, 31, 1535-1542.	3.9	120
86	Involvement of GABA systems in feedback regulation of glutamate-and GABA-mediated synaptic potentials in rat neostriatum.. Journal of Physiology, 1991, 440, 581-599.	2.9	119
87	A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice. PLoS ONE, 2010, 5, e11464.	2.5	119
88	Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. Neuropharmacology, 1999, 38, 323-326.	4.1	118
89	Mitochondria and the Link Between Neuroinflammation and Neurodegeneration. Journal of Alzheimer's Disease, 2010, 20, S369-S379.	2.6	118
90	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. Journal of Headache and Pain, 2019, 20, 92.	6.0	116

#	Article	IF	Citations
91	Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. Neuropsychopharmacology, 2007, 32, 1384-1390.	5.4	115
92	Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory. Behavioural Brain Research, 2009, 199, 108-118.	2.2	115
93	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18985-18990.	7.1	113
94	Cellular factors controlling neuronal vulnerability in the brain. Neurology, 2000, 55, 1249-1255.	1.1	111
95	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer's Research and Therapy, 2018, 10, 8.	6.2	111
96	Dopamine, Acetylcholine and Nitric Oxide Systems Interact to Induce Corticostriatal Synaptic Plasticity. Reviews in the Neurosciences, 2003, 14, 207-16.	2.9	110
97	Cortical spreading depression as a target for anti-migraine agents. Journal of Headache and Pain, 2013, 14, 62.	6.0	110
98	Intrinsic membrane properties of neostriatal neurons can account for their low level of spontaneous activity. Neuroscience, 1987, 20, 293-303.	2.3	106
99	l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiology of Disease, 2008, 29, 327-335.	4.4	105
100	Muscarine depolarizes rat substantia nigra zona compacta and ventral tegmental neurons in vitro through M1-like receptors. Journal of Pharmacology and Experimental Therapeutics, 1990, 253, 395-400.	2.5	105
101	Selective involvement of mGlu1 receptors in corticostriatal LTD. Neuropharmacology, 2001, 40, 839-846.	4.1	104
102	Global impact of COVID-19 on stroke care. International Journal of Stroke, 2021, 16, 573-584.	5.9	104
103	Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Movement Disorders, 2007, 22, 1481-1484.	3.9	103
104	Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. II. Modulation of High-Voltage-Activated Calcium Currents. Epilepsia, 1995, 36, 997-1002.	5.1	101
105	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology, 2008, 71, 1796-1803.	1.1	101
106	Differential role of CSF fatty acid binding protein 3, Î±-synuclein, and Alzheimerâ€™s disease core biomarkers in Lewy body disorders and Alzheimerâ€™s dementia. Alzheimer's Research and Therapy, 2017, 9, 52.	6.2	101
107	Pathophysiological basis of migraine prophylaxis. Progress in Neurobiology, 2009, 89, 176-192.	5.7	100
108	Activation of Group III Metabotropic Glutamate Receptors Depresses Glutamatergic Transmission at Corticostriatal Synapse. Neuropharmacology, 1997, 36, 845-851.	4.1	99

#	Article	IF	Citations
109	Metabotropic Glutamate Receptors and Cell-Type-Specific Vulnerability in the Striatum: Implication for Ischemia and Huntington's Disease. Experimental Neurology, 1999, 158, 97-108.	4.1	99
110	Molecular mechanisms underlying levodopa-induced dyskinesia. Movement Disorders, 2008, 23, S570-S579.	3.9	99
111	Hyperkinetic disorders and loss of synaptic downscaling. Nature Neuroscience, 2016, 19, 868-875.	14.8	98
112	Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinsonâ€™s Disease and Dementia with Lewy Bodies. Molecular Neurobiology, 2019, 56, 1344-1355.	4.0	97
113	Synaptic and intrinsic control of membrane excitability of neostriatal neurons. II. An in vitro analysis. Journal of Neurophysiology, 1990, 63, 663-675.	1.8	96
114	Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neuroscience and Biobehavioral Reviews, 1997, 21, 519-523.	6.1	96
115	Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends in Pharmacological Sciences, 2007, 28, 188-195.	8.7	96
116	Synaptic dysfunction in Parkinson's disease. Biochemical Society Transactions, 2010, 38, 493-497.	3.4	96
117	Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons. Journal of Neuroscience, 1994, 14, 6734-6743.	3.6	95
118	Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia. Stroke, 2006, 37, 1319-1326.	2.0	95
119	Sensitization, glutamate, and the link between migraine and fibromyalgia. Current Pain and Headache Reports, 2007, 11, 343-351.	2.9	95
120	Involvement of Corticotrophin-Releasing Factor and Orexin-A in Chronic Migraine and Medication-Overuse Headache: Findings From Cerebrospinal Fluid. Cephalalgia, 2008, 28, 714-722.	3.9	94
121	Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease. Journal of Neuroscience, 2011, 31, 12513-12522.	3.6	94
122	Performance of AÎ²1-40, AÎ²1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 29, 229-238.	2.6	93
123	Dopamine decreases cell excitability in rat striatal neurons by pre- and postsynaptic mechanisms. Brain Research, 1985, 358, 110-121.	2.2	92
124	Activation of quisqualate metabotropic receptors reduces glutamate and GABA-mediated synaptic potentials in the rat striatum. Neuroscience Letters, 1992, 139, 41-44.	2.1	92
125	Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission. Molecular and Cellular Neurosciences, 2001, 17, 1071-1083.	2.2	92
126	Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors. Journal of Neuroscience, 2004, 24, 8214-8222.	3.6	90

#	Article	IF	Citations
127	On the mechanisms underlying hypoxia-induced membrane depolarization in striatal neurons. Brain, 1995, 118, 1027-1038.	7.6	89
128	Blockade of M2-like muscarinic receptors enhances long-term potentiation at corticostriatal synapses. European Journal of Neuroscience, 1998, 10, 3020-3023.	2.6	89
129	Coactivation of GABA A and GABA B Receptor Results in Neuroprotection During In Vitro Ischemia. Stroke, 2004, 35, 596-600.	2.0	89
130	Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Movement Disorders, 2013, 28, 747-754.	3.9	88
131	c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death and Disease, 2014, 5, e1019-e1019.	6.3	88
132	Glutamate-Triggered Events Inducing Corticostriatal Long-Term Depression. Journal of Neuroscience, 1999, 19, 6102-6110.	3.6	87
133	Permissive role of interneurons in corticostriatal synaptic plasticity. Brain Research Reviews, 1999, 31, 1-5.	9.0	86
134	Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. Neuropharmacology, 2003, 44, 8-16.	4.1	86
135	Targeting striatal cholinergic interneurons in Parkinson's disease: Focus on metabotropic glutamate receptors. Neuropharmacology, 2003, 45, 45-56.	4.1	85
136	Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiology of Aging, 2009, 30, 34-40.	3.1	85
137	Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. Neuroscience, 2006, 140, 897-911.	2.3	84
138	Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia, 2010, 51, 274-279.	5.1	84
139	Muscarinic IPSPs in rat striatal cholinergic interneurones. Journal of Physiology, 1998, 510, 421-427.	2.9	83
140	Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. Movement Disorders, 2018, 33, 867-876.	3.9	82
141	Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain, 2019, 142, 1365-1385.	7.6	82
142	Levetiracetam monotherapy in Alzheimer patients with lateâ€onset seizures: a prospective observational study. European Journal of Neurology, 2007, 14, 1176-1178.	3.3	81
143	Pathological Synaptic Plasticity in the Striatum: Implications for Parkinson's Disease. NeuroToxicology, 2005, 26, 779-783.	3.0	80
144	Dopamine D2 Receptor-Mediated Inhibition of Dopaminergic Neurons in Mice Lacking D2L Receptors. Neuropsychopharmacology, 2002, 27, 723-726.	5.4	79

#	Article	IF	Citations
145	Abnormal Sensitivity to Cannabinoid Receptor Stimulation Might Contribute to Altered Gamma-Aminobutyric Acid Transmission in the Striatum of R6/2 Huntingtonâ€™s Disease Mice. Biological Psychiatry, 2005, 57, 1583-1589.	1.3	79
146	Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. Neurobiology of Disease, 2006, 22, 143-152.	4.4	79
147	Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. Annals of Neurology, 2000, 47, S60-8; discussion S68-9.	5.3	79
148	Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission. Annals of Neurology, 1992, 31, 366-373.	5.3	78
149	Vulnerability of Medium Spiny Striatal Neurons to Glutamate: Role of Na⁺/K⁺ ATPase. European Journal of Neuroscience, 1995, 7, 1674-1683.	2.6	78
150	Cocaine and Amphetamine Depress Striatal GABAergic Synaptic Transmission through D2 Dopamine Receptors. Neuropsychopharmacology, 2002, 26, 164-175.	5.4	78
151	Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain, 2004, 127, 1661-1669.	7.6	78
152	Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. Neuroscience, 2004, 129, 157-166.	2.3	77
153	Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. European Journal of Clinical Pharmacology, 2008, 64, 1-8.	1.9	77
154	Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N -Methyl-D-Aspartate Receptor Subunit. Biological Psychiatry, 2016, 79, 402-414.	1.3	77
155	Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain, 2002, 125, 2635-2645.	7.6	76
156	Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain, 1993, 116 (Pt 2), 433-52.	7.6	76
157	Voltageâ€dependent membrane potential oscillations of rat striatal fastâ€spiking interneurons. Journal of Physiology, 2003, 549, 121-130.	2.9	75
158	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiology of Aging, 2019, 73, 61-67.	3.1	75
159	The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. Life Sciences, 1992, 51, 711-718.	4.3	74
160	c-Jun N-terminal Kinase Regulates Soluble AÎ² Oligomers and Cognitive Impairment in AD Mouse Model. Journal of Biological Chemistry, 2011, 286, 43871-43880.	3.4	74
161	Ischemic Stroke Injury Is Mediated by Aberrant Cdk5. Journal of Neuroscience, 2014, 34, 8259-8267.	3.6	73
162	Dopamine modulates CA1 hippocampal neurons by elevating the threshold for spike generation: An in vitro study. Neuroscience, 1984, 13, 1105-1116.	2.3	72

#	Article	IF	Citations
163	A Synaptic Mechanism Underlying the Behavioral Abnormalities Induced by Manganese Intoxication. Neurobiology of Disease, 2001, 8, 419-432.	4.4	72
164	Is Pharmacological Neuroprotection Dependent on Reduced Glutamate Release?. Stroke, 2000, 31, 766-773.	2.0	71
165	Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiology of Disease, 2008, 30, 186-189.	4.4	71
166	Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140184.	4.0	71
167	Epilepsy, amyloid-Î², and D1 dopamine receptors: a possible pathogenetic link?. Neurobiology of Aging, 2016, 48, 161-171.	3.1	71
168	Sodium Influx Plays a Major Role in the Membrane Depolarization Induced by Oxygen and Glucose Deprivation in Rat Striatal Spiny Neurons. Stroke, 1999, 30, 171-179.	2.0	70
169	Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1224-1229.	1.9	70
170	Activation of metabotropic glutamate receptors induces an inward current in rat dopamine mesencephalic neurons. Neuroscience, 1993, 56, 399-407.	2.3	69
171	Activation of dopamine D1-like receptors excites LTS interneurons of the striatum. European Journal of Neuroscience, 2002, 15, 2049-2052.	2.6	69
172	Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: An immunohistological study. Purinergic Signalling, 2007, 3, 389-398.	2.2	69
173	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. Biological Psychiatry, 2010, 67, 567-574.	1.3	68
174	NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients. Frontiers in Cellular Neuroscience, 2015, 9, 245.	3.7	68
175	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. Scientific Reports, 2016, 6, 20926.	3.3	68
176	Endogenous Adenosine Mediates the Presynaptic Inhibition Induced by Aglycemia at Corticostriatal Synapses. Journal of Neuroscience, 1997, 17, 4509-4516.	3.6	67
177	L-Type Ca ²⁺ Channel Blockers Attenuate Electrical Changes and Ca ²⁺ Rise Induced by Oxygen/Glucose Deprivation in Cortical Neurons. Stroke, 1998, 29, 196-202.	2.0	67
178	Metabotropic Glutamate 2 Receptors Modulate Synaptic Inputs and Calcium Signals in Striatal Cholinergic Interneurons. Journal of Neuroscience, 2002, 22, 6176-6185.	3.6	67
179	Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease. Journal of Neuroscience, 2012, 32, 17921-17931.	3.6	67
180	Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia. Biological Psychiatry, 2015, 77, 106-115.	1.3	67

#	Article	IF	Citations
181	Heterogeneity of Metabotropic Glutamate Receptors in the Striatum: Electrophysiological Evidence. European Journal of Neuroscience, 1993, 5, 1370-1377.	2.6	66
182	Opposite Membrane Potential Changes Induced by Glucose Deprivation in Striatal Spiny Neurons and in Large Aspiny Interneurons. Journal of Neuroscience, 1997, 17, 1940-1949.	3.6	65
183	An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. British Journal of Pharmacology, 1999, 126, 689-696.	5.4	65
184	Postâ€ischaemic longâ€term synaptic potentiation in the striatum: a putative mechanism for cell typeâ€specific vulnerability. Brain, 2002, 125, 844-860.	7.6	64
185	Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons. Neuropharmacology, 2005, 49, 104-113.	4.1	64
186	Clinical-Biochemical Correlates of Migraine Attacks in Rizatriptan Responders and Non-Responders. Cephalalgia, 2006, 26, 257-265.	3.9	64
187	NR2B Subunit Exerts a Critical Role in Postischemic Synaptic Plasticity. Stroke, 2006, 37, 1895-1901.	2.0	63
188	Synaptic plasticity during recovery from permanent occlusion of the middle cerebral artery. Neurobiology of Disease, 2007, 27, 44-53.	4.4	63
189	Endogenous dopamine and dopaminergic agonists modulate synaptic excitation in neostriatum: Intracellular studies from naive and catecholamine-depleted rats. Neuroscience, 1988, 27, 145-157.	2.3	62
190	Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study. Epilepsy Research, 2008, 82, 223-226.	1.6	62
191	Motor learning and metaplasticity in striatal neurons: relevance for Parkinsonâ€™s disease. Brain, 2018, 141, 505-520.	7.6	62
192	Levetiracetam protects against kainic acid-induced toxicity. Life Sciences, 2004, 74, 1253-1264.	4.3	61
193	Cerebrospinal fluid Î²-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Neurobiology of Disease, 2009, 34, 484-486.	4.4	61
194	Risk factors of levodopa-induced dyskinesia in Parkinsonâ€™s disease: results from the PPMI cohort. Npj Parkinson's Disease, 2018, 4, 33.	5.3	61
195	Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiology of Aging, 2012, 33, 2138-2144.	3.1	60
196	Amyloid-Î²: a potential link between epilepsy and cognitive decline. Nature Reviews Neurology, 2021, 17, 469-485.	10.1	60
197	Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. Progress in Neurobiology, 2001, 63, 687-696.	5.7	59
198	Biochemical Changes in Endocannabinoid System are Expressed in Platelets of Female but not Male Migraineurs. Cephalalgia, 2006, 26, 277-281.	3.9	59

#	Article	IF	Citations
199	Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-Î² 1a, and high doses of immunoglobulins. Multiple Sclerosis Journal, 2007, 13, 313-331.	3.0	58
200	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3848-3857.	7.1	58
201	Obsessiveâ€Compulsive Disorder and Migraine With Medicationâ€Overuse Headache. Headache, 2009, 49, 1005-1013.	3.9	56
202	Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons. Neuropharmacology, 2001, 40, 460-463.	4.1	55
203	Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits. Parkinsonism and Related Disorders, 2007, 13, S259-S262.	2.2	55
204	Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. European Neuropsychopharmacology, 2014, 24, 1289-1297.	0.7	55
205	The modulation of calcium currents by the activation of mGluRs. Molecular Neurobiology, 1996, 13, 81-95.	4.0	54
206	Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. Neuroscience, 2005, 133, 831-840.	2.3	54
207	Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. Journal of Neuroscience, 2008, 28, 8040-8052.	3.6	54
208	Muscarinic modulation of calcium dependent plateau potentials in rat neostriatal neurons. Pflugers Archiv European Journal of Physiology, 1986, 407, 482-487.	2.8	53
209	Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology, 2007, 53, 783-789.	4.1	53
210	Aortic stiffness and pulse wave reflection in young subjects with migraine. Neurology, 2010, 75, 960-966.	1.1	53
211	Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. Neurobiology of Disease, 2016, 86, 140-153.	4.4	53
212	Clinical features and outcome of 6 new patients carrying de novo <i>KCNB1</i> gene mutations. Neurology: Genetics, 2017, 3, e206.	1.9	53
213	Tissue plasminogen activator is required for corticostriatal long-term potentiation. European Journal of Neuroscience, 2002, 16, 713-721.	2.6	52
214	Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neuroscience Letters, 2008, 435, 223-228.	2.1	52
215	The Endocannabinoid System in Parkinsons Disease. Current Pharmaceutical Design, 2008, 14, 2337-2346.	1.9	52
216	Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. I. Modulation of Corticostriatal Synaptic Transmission. Epilepsia, 1995, 36, 990-996.	5.1	51

#	Article	IF	Citations
217	Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: Role of Na+/K+ ATPase. Neurobiology of Disease, 2006, 23, 54-60.	4.4	51
218	Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 40263.	3.3	51
219	Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatum. Neuroscience Letters, 1990, 118, 99-102.	2.1	50
220	Removing Pathogenic Memories: A Neurobiology of Psychotherapy. Molecular Neurobiology, 2005, 32, 123-132.	4.0	50
221	Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Brain, 2008, 132, 285-287.	7.6	50
222	Neural 17Î²-estradiol facilitates long-term potentiation in the hippocampal CA1 region. Neuroscience, 2011, 192, 67-73.	2.3	50
223	CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1281-1288.	2.6	49
224	Dopamine-dependent early synaptic and motor dysfunctions induced by Î±-synuclein in the nigrostriatal circuit. Brain, 2021, 144, 3477-3491.	7.6	49
225	Responses of rat substantia nigra compacta neurones to Lâ€DOPA. British Journal of Pharmacology, 1990, 100, 257-260.	5.4	48
226	Effects of anoxia on rat midbrain dopamine neurons. Journal of Neurophysiology, 1994, 71, 1165-1173.	1.8	48
227	Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Molecular and Cellular Neurosciences, 2004, 25, 9-20.	2.2	47
228	Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities. Movement Disorders, 2020, 35, 1731-1744.	3.9	47
229	Electrophysiological Recordings and Calcium Measurements in Striatal Large Aspiny Interneurons in Response to Combined O₂/Glucose Deprivation. Journal of Neurophysiology, 1999, 81, 2508-2516.	1.8	46
230	Inhibition of Persistent Sodium Current Fraction and Voltage-gated L-type Calcium Current by Propofol in Cortical Neurons: Implications for Its Antiepileptic Activity. Epilepsia, 2005, 46, 624-635.	5.1	46
231	The Brain Cytoplasmic RNA BC1 Regulates Dopamine D2 Receptor-Mediated Transmission in the Striatum. Journal of Neuroscience, 2007, 27, 8885-8892.	3.6	46
232	The mechanism of amphetamineâ€induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording <i>in vitro</i>. British Journal of Pharmacology, 1989, 98, 127-134.	5.4	45
233	Electrophysiological actions of felbamate on rat striatal neurones. British Journal of Pharmacology, 1995, 116, 2053-2061.	5.4	45
234	Activation of Î²1-Adrenoceptors Excites Striatal Cholinergic Interneurons through a cAMP-Dependent, Protein Kinase-Independent Pathway. Journal of Neuroscience, 2003, 23, 5272-5282.	3.6	45

#	Article	IF	Citations
235	NF-Î°B Activity and iNOS Expression in Monocytes from Internal Jugular Blood of Migraine Without Aura Patients During Attacks. Cephalalgia, 2006, 26, 1071-1079.	3.9	45
236	Role of the dorsal hippocampus in object memory load. Learning and Memory, 2012, 19, 211-218.	1.3	45
237	Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinsonâ€™s Disease Patients. NeuroMolecular Medicine, 2012, 14, 84-90.	3.4	45
238	Evidence of hydrogen sulfide involvement in amyotrophic lateral sclerosis. Annals of Neurology, 2015, 77, 697-709.	5.3	45
239	Stimulation of Nitric Oxideâ€“cGMP Pathway Excites Striatal Cholinergic Interneurons via Protein Kinase G Activation. Journal of Neuroscience, 2001, 21, 1393-1400.	3.6	44
240	Brain arteriovenous malformations and seizures: an Italian study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 284-288.	1.9	44
241	An evolving redefinition of autoimmune encephalitis. Autoimmunity Reviews, 2019, 18, 155-163.	5.8	44
242	Lithium Treatment Blocks Long-Term Synaptic Depression in the Striatum. Neuron, 1993, 10, 955-962.	8.1	43
243	Experimental Parkinsonism Modulates Multiple Genes Involved in the Transduction of Dopaminergic Signals in the Striatum. Neurobiology of Disease, 2002, 10, 387-395.	4.4	43
244	Chronic Cocaine Prevents Depotentiation at Corticostriatal Synapses. Biological Psychiatry, 2006, 60, 436-443.	1.3	43
245	Striatumâ€“hippocampus balance: From physiological behavior to interneuronal pathology. Progress in Neurobiology, 2011, 94, 102-114.	5.7	43
246	Endogenous 17ÃŽÂ²-estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. Frontiers in Cellular Neuroscience, 2015, 9, 192.	3.7	43
247	Glial Cell Line-Derived Neurotrophic Factor and Somatostatin Levels in Cerebrospinal Fluid of Patients Affected by Chronic Migraine and Fibromyalgia. Cephalalgia, 2006, 26, 409-415.	3.9	42
248	Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. Journal of Neuroimmunology, 2007, 188, 146-158.	2.3	41
249	Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinsonâ€™s disease. Progress in Brain Research, 2010, 183, 169-182.	1.4	41
250	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology, 2019, 266, 2157-2163.	3.6	41
251	Epileptiform discharge induced by 4-aminopyridine in magnesium-free medium in neocortical neurons: physiological and pharmacological characterization. Neuroscience, 1997, 81, 189-197.	2.3	40
252	Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? insights from in vitro studies. Neurobiology of Disease, 2003, 12, 82-88.	4.4	40

#	Article	IF	Citations
253	NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: Implications for Huntington's disease. Neuroscience Letters, 2008, 434, 241-246.	2.1	40
254	BDNFâ€"TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior. Nature Communications, 2013, 4, 2031.	12.8	40
255	Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiology of Disease, 2017, 108, 54-64.	4.4	40
256	Neurotensin induces an inward current in rat mesencephalic dopaminergic neurons. Neuroscience Letters, 1993, 153, 192-196.	2.1	39
257	Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology, 1998, 37, 1063-1070.	4.1	39
258	Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinsonâ€™s disease. Amino Acids, 2007, 32, 189-195.	2.7	39
259	Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia. Experimental Neurology, 2011, 232, 240-250.	4.1	39
260	Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. Journal of Neuroscience, 2012, 32, 16106-16119.	3.6	39
261	Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities. Journal of Neural Transmission, 2018, 125, 1263-1271.	2.8	39
262	Effect of lockdown on the management of ischemic stroke: an Italian experience from a COVID hospital. Neurological Sciences, 2020, 41, 2309-2313.	1.9	39
263	Adenosine-mediated inhibition of striatal GABAergic synaptic transmission during in vitro ischaemia. Brain, 2001, 124, 1855-1865.	7.6	38
264	N-Methyl-d-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons. Journal of Biological Chemistry, 2012, 287, 18103-18114.	3.4	38
265	Intermittent thetaâ€burst stimulation rescues dopamineâ€dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity. Movement Disorders, 2017, 32, 1035-1046.	3.9	38
266	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Reports, 2021, 37, 110094.	6.4	38
267	Transmitter Release Associated with Long-term Synaptic Depression in Rat Corticostriatal Slices. European Journal of Neuroscience, 1995, 7, 1889-1894.	2.6	37
268	Antiepileptic Drugs on Calcium Currents Recorded from Cortical and PAG Neurons: Therapeutic Implications for Migraine. Cephalalgia, 2008, 28, 1315-1326.	3.9	37
269	Ictal Epileptic Headache Mimicking Status Migrainosus: EEG and DWIâ€MRI Findings. Headache, 2011, 51, 160-162.	3.9	37
270	Mechanisms underlying altered striatal synaptic plasticity in old A53T-Î± synuclein overexpressing mice. Neurobiology of Aging, 2012, 33, 1792-1799.	3.1	37

#	Article	IF	Citations
271	COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson's Disease in the Elderly. Frontiers in Psychiatry, 2020, 11, 581144.	2.6	37
272	Selective depression of synaptic transmission by tetanus toxin: A comparative study on hippocampal and neostriatal slices. Neuroscience, 1989, 30, 663-670.	2.3	36
273	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91.	3.3	36
274	Epilepsy in hemiplegic migraine: Genetic mutations and clinical implications. Cephalalgia, 2018, 38, 361-373.	3.9	36
275	Assessment of neurological manifestations in hospitalized patients with COVIDâ€19. European Journal of Neurology, 2020, 27, 2322-2328.	3.3	36
276	A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Neurology, 1996, 47, 557-562.	1.1	35
277	Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinsonâ€™s disease. Cell Death and Disease, 2018, 9, 204.	6.3	35
278	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. Journal of Neurology, 2018, 265, 2684-2687.	3.6	35
279	Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 157.	4.8	35
280	A voltage-clamp analysis of NMDA-induced responses on dopaminergic neurons of the rat subtantia nigra zona compacta and ventral tegmental area. Brain Research, 1992, 593, 51-56.	2.2	34
281	CSF proteome analysis in multiple sclerosis patients by twoâ€dimensional electrophoresis. European Journal of Neurology, 2008, 15, 998-1001.	3.3	34
282	A ¹H magnetic resonance spectroscopy study in patients with obstructive sleep apnea. European Journal of Neurology, 2008, 15, 1058-1064.	3.3	34
283	New synaptic and molecular targets for neuroprotection in Parkinson's disease. Movement Disorders, 2013, 28, 51-60.	3.9	34
284	Evidence of practice effect in CANTAB spatial working memory test in a cohort of patients with mild cognitive impairment. Applied Neuropsychology Adult, 2018, 25, 237-248.	1.2	34
285	Quantal Release of Dopamine and Action Potential Firing Detected in Midbrain Neurons by Multifunctional Diamond-Based Microarrays. Frontiers in Neuroscience, 2019, 13, 288.	2.8	34
286	GABA depolarizes neurons in the rat striatum: An in vivo study. Synapse, 1991, 8, 38-40.	1.2	33
287	Acanthocytosis as a predisposing factor for non-ketotic hyperglycaemia induced chorea-ballism. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1717-1719.	1.9	33
288	A magnetization transfer study of mild and advanced Parkinsonâ€™s disease. European Journal of Neurology, 2011, 18, 471-477.	3.3	33

#	Article	IF	Citations
289	Palinopsia in patients with migraine: A case-control study. Cephalalgia, 2011, 31, 999-1004.	3.9	33
290	Calcium signaling and neuronal vulnerability to ischemia in the striatum. Cell Calcium, 2004, 36, 277-284.	2.4	32
291	Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. Experimental Neurology, 2007, 207, 218-226.	4.1	32
292	TrkB/BDNF-Dependent Striatal Plasticity and Behavior in a Genetic Model of Epilepsy: Modulation by Valproic Acid. Neuropsychopharmacology, 2010, 35, 1531-1540.	5.4	32
293	Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum. Molecular Pharmacology, 2001, 60, 808-15.	2.3	32
294	Differences in Extracellular Matrix Production and Basic Fibroblast Growth Factor Response in Skin Fibroblasts from Sporadic and Familial Alzheimerâ€™s Disease. Molecular Medicine, 2007, 13, 542-550.	4.4	31
295	Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 151-161.	3.8	31
296	The validity and reliability of the Italian Olfactory Identification Test (IOIT) in healthy subjects and in Parkinson's disease patients. Parkinsonism and Related Disorders, 2012, 18, 788-793.	2.2	31
297	The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinsonâ€™s disease patients. Scientific Reports, 2019, 9, 8898.	3.3	31
298	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. Journal of Neuroimmunology, 2020, 339, 577108.	2.3	31
299	Plastic abnormalities in experimental Huntington's disease. Current Opinion in Pharmacology, 2007, 7, 106-111.	3.5	30
300	Medication overuse headache: Neurobiological, behavioural and therapeutic aspects. Pain, 2010, 150, 222-224.	4.2	30
301	Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Brain Research, 2015, 1621, 205-213.	2.2	30
302	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 123-133.	3.1	30
303	Neuropsychiatric adverse events of antiepileptic drugs in brain tumourâ€related epilepsy: an Italian multicentre prospective observational study. European Journal of Neurology, 2017, 24, 1283-1289.	3.3	30
304	Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences. Progress in Neurobiology, 2018, 169, 55-75.	5.7	30
305	An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients. Frontiers in Neurology, 2020, 11, 564.	2.4	30
306	Impaired Excitatory Transmission in the Striatum of Rats Chronically Intoxicated with Manganese. Experimental Neurology, 2001, 172, 469-476.	4.1	29

#	Article	IF	Citations
307	Medicationâ€“overuse headache: pathophysiological insights. Journal of Headache and Pain, 2005, 6, 199-202.	6.0	29
308	Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide. Movement Disorders, 2008, 23, 468-470.	3.9	29
309	Modulatory role of androgenic and estrogenic neurosteroids in determining the direction of synaptic plasticity in the CA1 hippocampal region of male rats. Physiological Reports, 2013, 1, e00185.	1.7	29
310	A53T in a parkinsonian family: a clinical update of the SNCA phenotypes. Journal of Neural Transmission, 2016, 123, 1301-1307.	2.8	29
311	Kainic acid on neostriatal neurons intracellularly recorded in vitro: electrophysiological evidence for differential neuronal sensitivity. Journal of Neuroscience, 1990, 10, 3960-3969.	3.6	28
312	Role of Ca2+in striatal LTD and LTP. Seminars in Neuroscience, 1996, 8, 321-328.	2.2	28
313	Involvement of Intracellular Calcium Stores during Oxygen/Glucose Deprivation in Striatal Large Aspiny Interneurons. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 839-846.	4.3	28
314	Cell-type specificity of mGluR activation in striatal neuronal subtypes. Amino Acids, 2000, 19, 119-129.	2.7	28
315	Cyclic Vomiting Syndrome, Migraine, and Epilepsy: A Common Underlying Disorder?. Headache, 2003, 43, 407-409.	3.9	28
316	Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. Biological Psychiatry, 2010, 67, 666-671.	1.3	28
317	Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. Experimental Neurology, 2010, 221, 217-224.	4.1	28
318	A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. Cephalalgia, 2014, 34, 68-72.	3.9	28
319	Shapiro's syndrome: Defining the clinical spectrum of the spontaneous paroxysmal hypothermia syndrome. European Journal of Paediatric Neurology, 2014, 18, 453-457.	1.6	28
320	Diagnostic Accuracy of Parkinson Disease by Support Vector Machine (SVM) Analysis of 123I-FP-CIT Brain SPECT Data. Medicine (United States), 2014, 93, e228.	1.0	28
321	Endogenous Dopamine Amplifies Ischemic Long-Term Potentiation via D1 Receptors. Stroke, 2002, 33, 2978-2984.	2.0	27
322	NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. Experimental Neurology, 2006, 202, 470-479.	4.1	27
323	Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine. Neuropharmacology, 2006, 50, 917-923.	4.1	27
324	Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology, 2012, 79, 1182-1184.	1.1	27

#	Article	IF	Citations
325	Performance Evaluation of an Automated ELISA System for Alzheimerâ€™s Disease Detection in Clinical Routine. Journal of Alzheimer's Disease, 2016, 54, 55-67.	2.6	27
326	Prognostic factors in children with PRES and hematologic diseases. Acta Neurologica Scandinavica, 2016, 134, 474-483.	2.1	27
327	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. Neurobiology of Disease, 2018, 113, 97-108.	4.4	27
328	Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?. Neurobiology of Disease, 2019, 132, 104579.	4.4	27
329	Complexity of Motor Sequences and Cortical Reorganization in Parkinson's Disease: A Functional MRI Study. PLoS ONE, 2013, 8, e66834.	2.5	27
330	Modulation of gene expression following long-term synaptic depression in the striatum. Molecular Brain Research, 1999, 72, 89-96.	2.3	26
331	Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: Results of a populationâ€based study. Movement Disorders, 2007, 22, 540-545.	3.9	26
332	Effect of MTHFR Polymorphisms on Hyperhomocysteinemia in Levodopa-treated Parkinsonian Patients. NeuroMolecular Medicine, 2007, 9, 249-254.	3.4	26
333	Epilepsyâ€induced abnormal striatal plasticity in Bassoon mutant mice. European Journal of Neuroscience, 2009, 29, 1979-1993.	2.6	26
334	Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment. Neuroscience, 2009, 163, 735-740.	2.3	26
335	Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4375-84.	7.1	26
336	Developmental impaired Akt signaling in the Shank1 and Shank3 double knock-out mice. Molecular Psychiatry, 2021, 26, 1928-1944.	7.9	26
337	Striatal glutamatergic hyperactivity in Parkinson's disease. Neurobiology of Disease, 2022, 168, 105697.	4.4	26
338	SHORT COMUNICATIONEarly sodium elevations induced by combined oxygen and glucose deprivation in pyramidal cortical neurons. European Journal of Neuroscience, 1998, 10, 3572-3574.	2.6	25
339	Acetyl-l-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology, 2008, 55, 223-229.	4.1	25
340	Occipital arteriovenous malformations and migraine. Cephalalgia, 2011, 31, 1320-1324.	3.9	25
341	Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice. Experimental Neurology, 2014, 261, 320-327.	4.1	25
342	Neo-synthesis of estrogenic or androgenic neurosteroids determine whether long-term potentiation or depression is induced in hippocampus of male rat. Frontiers in Cellular Neuroscience, 2015, 9, 376.	3.7	25

#	Article	IF	Citations
343	The Project for a Scientific Psychology (1895): a Freudian anticipation of LTP-memory connection theory. Brain Research Reviews, 2004, 46, 310-314.	9.0	24
344	Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. Neurobiology of Disease, 2004, 15, 407-414.	4.4	24
345	Phyto-oestrogens in the Prophylaxis of Menstrual Migraine. Clinical Neuropharmacology, 2004, 27, 137-140.	0.7	24
346	A novel spinocerebellar ataxia type 15 family with involuntary movements and cognitive decline. European Journal of Neurology, 2011, 18, 1263-1265.	3.3	24
347	NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology. Neurobiology of Disease, 2019, 121, 338-349.	4.4	24
348	Time trends, frequency, characteristics and prognosis of shortâ€duration transient global amnesia. European Journal of Neurology, 2020, 27, 887-893.	3.3	24
349	Pharmacological Inhibition of the Na ⁺ /Ca ²⁺ Exchanger Enhances Depolarizations Induced by Oxygen/Glucose Deprivation but Not Responses to Excitatory Amino Acids in Rat Striatal Neurons. Stroke, 1999, 30, 1687-1694.	2.0	23
350	Coordinate high-frequency pattern of stimulation and calcium levels control the induction of LTP in striatal cholinergic interneurons. Learning and Memory, 2004, 11, 755-760.	1.3	23
351	Sipatrigine (BW 619C89) is a Neuroprotective Agent and a Sodium Channel and Calcium Channel Inhibitor. CNS Neuroscience & Therapeutics, 2000, 6, 111-134.	4.0	23
352	Mitochondrial Toxins in Basal Ganglia Disorders: From Animal Models to Therapeutic Strategies. Current Neuropharmacology, 2006, 4, 69-75.	2.9	23
353	mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP. Experimental Neurology, 2010, 226, 328-331.	4.1	23
354	A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: Modulation by zonisamide. Neurobiology of Disease, 2011, 44, 185-191.	4.4	23
355	Hippocampal enlargement in Bassoon-mutant mice is associated with enhanced neurogenesis, reduced apoptosis, and abnormal BDNF levels. Cell and Tissue Research, 2011, 346, 11-26.	2.9	23
356	Theta-burst stimulation and striatal plasticity in experimental parkinsonism. Experimental Neurology, 2012, 236, 395-398.	4.1	23
357	Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid. PLoS ONE, 2014, 9, e101453.	2.5	23
358	Abnormal cortical lysosomal Î²-hexosaminidase and Î²-galactosidase activity at post-synaptic sites during Alzheimer's disease progression. International Journal of Biochemistry and Cell Biology, 2015, 58, 62-70.	2.8	23
359	Practical Considerations for the Treatment of Elderly Patients with Migraine. Drugs and Aging, 2006, 23, 461-489.	2.7	22
360	Pathways of neurodegeneration and experimental models of basal ganglia disorders: Downstream effects of mitochondrial inhibition. European Journal of Pharmacology, 2006, 545, 65-72.	3.5	22

#	Article	IF	Citations
361	Ischemic bilateral hippocampal dysfunction during transient global amnesia. Neurology, 2007, 69, 493-493.	1.1	22
362	ACh/Dopamine Crosstalk in Motor Control and Reward: A Crucial Role for Î±6-Containing Nicotinic Receptors?. Neuron, 2008, 60, 4-7.	8.1	22
363	Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. Neurobiology of Disease, 2018, 118, 1-8.	4.4	22
364	Stimulus frequency, calcium levels and striatal synaptic plasticity. NeuroReport, 2003, 14, 419-422.	1.2	21
365	Mortalin inhibition in experimental Parkinson's disease. Movement Disorders, 2011, 26, 1639-1647.	3.9	21
366	Clinical Aspects and Management of Levodopa-Induced Dyskinesia. Parkinson's Disease, 2012, 2012, 1-12.	1.1	21
367	Magnetization transfer MRI in dementia disorders, Huntington's disease and parkinsonism. Journal of the Neurological Sciences, 2015, 353, 1-8.	0.6	21
368	Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study. Epilepsy and Behavior, 2019, 101, 106592.	1.7	21
369	Responses of rat mesencephalic dopaminergic neurons to a prolonged period of oxygen deprivation. Neuroscience, 1994, 63, 757-764.	2.3	20
370	Early ionic and membrane potential changes caused by the pesticide rotenone in striatal cholinergic interneurons. Experimental Neurology, 2004, 185, 169-181.	4.1	20
371	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 228-232.	2.0	20
372	Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts. Stroke, 2019, 50, 2555-2557.	2.0	20
373	Hippocampal epileptogenesis in autoimmune encephalitis. Annals of Clinical and Translational Neurology, 2019, 6, 2261-2269.	3.7	20
374	Bidirectional Synaptic Plasticity Is Driven by Sex Neurosteroids Targeting Estrogen and Androgen Receptors in Hippocampal CA1 Pyramidal Neurons. Frontiers in Cellular Neuroscience, 2019, 13, 534.	3.7	20
375	Immunological Profile of Silent Brain Infarction and Lacunar Stroke. PLoS ONE, 2013, 8, e68428.	2.5	20
376	Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. Journal of Neuroinflammation, 2021, 18, 259.	7.2	20
377	Depletion of catecholamines reveals inhibitory effects of bromocryptine and lysuride on neostriatal neurones recorded intracellularly in vitro. Neuropharmacology, 1988, 27, 579-587.	4.1	19
378	Hypoglycemia, Hypoxia, and Ischemia in a Corticostriatal Slice Preparation: Electrophysiologic Changes and Ascorbyl Radical Formation. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 868-875.	4.3	19

#	Article	IF	Citations
379	A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Experimental Neurology, 2009, 217, 231-234.	4.1	19
380	The validation of an Italian version of the Freezing of Gait Questionnaire. Neurological Sciences, 2015, 36, 759-764.	1.9	19
381	Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	19
382	Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine. Frontiers in Neurology, 2017, 8, 655.	2.4	19
383	Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?. Cephalalgia, 2018, 38, 274-282.	3.9	19
384	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140537.	2.3	19
385	Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. Neurobiology of Disease, 2020, 140, 104848.	4.4	19
386	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. Frontiers in Neuroscience, 2021, 15, 672954.	2.8	19
387	Effects of glycine on neurons in the rat substantia nigra zona compacta: In vitro electrophysiological study. Synapse, 1990, 5, 190-200.	1.2	18
388	Chapter 19 Chemical modulation of synaptic transmission in the striatum. Progress in Brain Research, 1993, 99, 299-308.	1.4	18
389	Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. Experimental Neurology, 2003, 182, 461-469.	4.1	18
390	Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway. Neuropharmacology, 2004, 46, 761-769.	4.1	18
391	l-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. Neuroscience Letters, 2006, 398, 211-214.	2.1	18
392	A Combination of CSF Tau Ratio and Midsaggital Midbraintopons Atrophy for the Early Diagnosis of Progressive Supranuclear Palsy. Journal of Alzheimer's Disease, 2010, 22, 195-203.	2.6	18
393	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. PLoS ONE, 2012, 7, e38312.	2.5	18
394	Interaction between basal ganglia and limbic circuits in learning and memory processes. Parkinsonism and Related Disorders, 2016, 22, S65-S68.	2.2	18
395	Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. Frontiers in Aging Neuroscience, 2020, 12, 230.	3.4	18
396	Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience. Brain Sciences, 2021, 11, 980.	2.3	18

#	Article	IF	Citations
397	Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey. Frontiers in Neurology, 2020, 11, 616550.	2.4	18
398	Immunological findings in patients with migraine and other primary headaches: a narrative review. Clinical and Experimental Immunology, 2022, 207, 11-26.	2.6	18
399	Autonomic Dysfunction during Acute SARS-CoV-2 Infection: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 3883.	2.4	18
400	Hypoxia-Induced Electrical Changes in Striatal Neurons. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 1141-1145.	4.3	17
401	Neurophysiology of Parkinson's disease: from basic research to clinical correlates. Clinical Neurophysiology, 1999, 110, 2006-2013.	1.5	17
402	Functional interactions within striatal microcircuit in animal models of Huntington's disease. Neuroscience, 2012, 211, 165-184.	2.3	17
403	Protective Effects of Zonisamide Against Rotenone-Induced Neurotoxicity. Neurochemical Research, 2013, 38, 2631-2639.	3.3	17
404	Interferon-Î²1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence. Neurobiology of Disease, 2014, 62, 387-393.	4.4	17
405	Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis. European Journal of Neurology, 2014, 21, 648-653.	3.3	17
406	Interferon-Î²1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors. Neuropharmacology, 2016, 100, 98-105.	4.1	17
407	Selective inhibition of mitochondrial sodium-calcium exchanger protects striatal neurons from Î±-synuclein plus rotenone induced toxicity. Cell Death and Disease, 2019, 10, 80.	6.3	17
408	Potassium ions play a role in the glycine-induced inhibition of rat substantia nigra zona compacta neurones. Brain Research, 1988, 462, 199-203.	2.2	16
409	1-Deprenyl Test in Migraine: Neuroendocrinological Aspects. Cephalalgia, 1993, 13, 406-409.	3.9	16
410	Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study. Cephalalgia, 2011, 31, 543-549.	3.9	16
411	Multitarget disease-modifying therapy in Parkinson's disease?. Lancet Neurology, The, 2015, 14, 975-976.	10.2	16
412	Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression. Neuropharmacology, 2016, 101, 341-350.	4.1	16
413	The Italian version of cognitive function instrument (CFI): reliability and validity in a cohort of healthy elderly. Neurological Sciences, 2018, 39, 111-118.	1.9	16
414	T2*-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson's disease. Neurobiology of Aging, 2019, 80, 91-98.	3.1	16

#	Article	IF	Citations
415	Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. Frontiers in Immunology, 2021, 12, 644294.	4.8	16
416	Migraine with Aura-Like Syndrome Due to Arteriovenous Malformation. The Clinical Value of Transcranial Doppler in Early Diagnosis. Cephalalgia, 1992, 12, 115-119.	3.9	15
417	Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an <i>in vitro</i> study. British Journal of Pharmacology, 1996, 117, 528-532.	5.4	15
418	Hypoxia in striatal and cortical neurones. NeuroReport, 1997, 8, 1143-1147.	1.2	15
419	Mutant huntingtin goes straight to the heart. Nature Neuroscience, 2002, 5, 711-712.	14.8	15
420	Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. Neuroscience Letters, 2006, 410, 6-10.	2.1	15
421	Hyperhomocysteinemia recurrence in levodopaâ€treated Parkinsonâ€™s disease patients. European Journal of Neurology, 2010, 17, 661-665.	3.3	15
422	Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia. Parkinson's Disease, 2012, 2012, 1-10.	1.1	15
423	From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinsonâ€™s Disease: Lessons From LRRK2. Frontiers in Cellular Neuroscience, 2020, 14, 158.	3.7	15
424	Unprotected stroke management in an undiagnosed case of Severe Acute Respiratory Syndrome Coronavirus 2 infection. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104981.	1.6	15
425	Mechanical thrombectomy in acute ischemic stroke due to large vessel occlusion in the anterior circulation and low baseline National Institute of Health Stroke Scale score: a multicenter retrospective matched analysis. Neurological Sciences, 2022, 43, 3105-3112.	1.9	15
426	A-current in rat globus pallidus: A whole-cell voltage clamp study on acutely dissociated neurons. Neuroscience Letters, 1992, 144, 4-8.	2.1	14
427	A Possible Mechanism for the Aglycemia-Induced Depression of Glutamatergic Excitation in the Striatum. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 1121-1126.	4.3	14
428	An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease. Neurological Sciences, 2001, 22, 61-62.	1.9	14
429	Striatal synaptic changes in experimental parkinsonism: Role of NMDA receptor trafficking in PSD. Parkinsonism and Related Disorders, 2008, 14, S145-S149.	2.2	14
430	Targeting metabotropic glutamate receptors as a new strategy against levodopaâ€induced dyskinesia in Parkinson's disease?. Movement Disorders, 2014, 29, 715-719.	3.9	14
431	The <scp>S</scp>mall <scp>GTP</scp>â€<scp>B</scp>inding <scp>P</scp>rotein <scp>R</scp>hes <scp>I</scp>nfluences <scp>N</scp>igrostriatalâ€<scp>D</scp>ependent <scp>M</scp>otor <scp>B</scp>ehavior <scp>D</scp>uring <scp>A</scp>ging. Movement Disorders, 2016, 31, 583-589.	3.9	14
432	Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs. Neurochemical Research, 2016, 41, 340-352.	3.3	14

#	Article	IF	Citations
433	Incidence and prevalence of Parkinsonâ€™s disease in the Italian region of Umbria: a population-based study using healthcare administrative databases. Neurological Sciences, 2019, 40, 1709-1712.	1.9	14
434	High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimerâ€™s disease. Amino Acids, 2021, 53, 435-449.	2.7	14
435	Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. Journal of Personalized Medicine, 2021, 11, 265.	2.5	14
436	Physiology and pharmacology of dopamine D ₂ â€receptors. Neurology, 1989, 39, 1106-1106.	1.1	14
437	A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19. Scientific Reports, 2021, 11, 21136.	3.3	14
438	Instrumental Evaluation of COVID-19 Related Dysautonomia in Non-Critically-Ill Patients: An Observational, Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 5861.	2.4	14
439	Nomifensine but not amantadine increases dopamine-induced responses on rat substantia nigra zona compacta neurons. Neuroscience Letters, 1991, 131, 145-148.	2.1	13
440	Language Disturbances as a Side Effect of Prophylactic Treatment of Migraine. Headache, 2007, 48, 070623002213001-???.	3.9	13
441	Ischemic-LTP in Striatal Spiny Neurons of both Direct and Indirect Pathway Requires the Activation of D1-Like Receptors and NO/Soluble Guanylate Cyclase/cGMP Transmission. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 278-286.	4.3	13
442	Subclinical Visuospatial Impairment in ParkinsonÃ¢â,¬â„¢s Disease: The Role of Basal Ganglia and Limbic System. Frontiers in Neurology, 2014, 5, 152.	2.4	13
443	Lacosamide protects striatal and hippocampal neurons from inÂvitro ischemia without altering physiological synaptic plasticity. Neuropharmacology, 2018, 135, 424-430.	4.1	13
444	Stroke and COVID19: Not only a large-vessel disease. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105074.	1.6	13
445	Dural arteriovenous fistulas and headache features: an observational study. Journal of Headache and Pain, 2020, 21, 6.	6.0	13
446	Changes of olfactory tract in Parkinsonâ€™s disease: a DTI tractography study. Neuroradiology, 2021, 63, 235-242.	2.2	13
447	Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study. PLoS ONE, 2014, 9, e96806.	2.5	13
448	Electrophysiological effects of amineptine on neurones of the rat substantia nigra pars compacta: evidence for an inhibition of the dopamine uptake system. British Journal of Pharmacology, 1991, 104, 700-704.	5.4	12
449	Tissue plasminogen activator is required for striatal post-ischemic synaptic potentiation. NeuroReport, 2002, 13, 115-118.	1.2	12
450	Skin biopsy: a new diagnostic tool for autonomic dysfunctions in Parkinson's disease?. Lancet Neurology, The, 2007, 6, 848-849.	10.2	12

#	Article	IF	Citations
451	Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. Journal of Neurology, 2011, 258, 323-324.	3.6	12
452	Expression of cathepsins S and D signals a distinctive biochemical trait in CD34⁺ hematopoietic stem cells of relapsingâ€“remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1443-1453.	3.0	12
453	Retinopathy during interferon-Î² treatment for multiple sclerosis: case report and review of the literature. Journal of Neurology, 2016, 263, 422-427.	3.6	12
454	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. Journal of the Neurological Sciences, 2017, 379, 236-240.	0.6	12
455	Late onset epilepsy and Alzheimerâ€™s disease: exploring the dual pathogenic role of amyloid-Î². Brain, 2018, 141, e60-e60.	7.6	12
456	Substantia nigra hyperechogenicity in essential tremor and Parkinson's disease: a longitudinal study. European Journal of Neurology, 2019, 26, 1370-1376.	3.3	12
457	Decreased Rhes mRNA levels in the brain of patients with Parkinsonâ€™s disease and MPTP-treated macaques. PLoS ONE, 2017, 12, e0181677.	2.5	12
458	Autonomic dysfunction in non-critically ill COVID-19 patients during the acute phase of disease: an observational, cross-sectional study. Neurological Sciences, 2022, 43, 4635-4643.	1.9	12
459	Dopamine uptake inhibition potentiates the effects of l-DOPA on rat substantia nigra zona compacta neurons. Neuroscience Letters, 1991, 126, 79-82.	2.1	11
460	Electrophysiology of Sipatrigine: A Lamotrigine Derivative Exhibiting Neuroprotective Effects. Experimental Neurology, 2000, 162, 171-179.	4.1	11
461	Behavioural learning-induced increase in spontaneous GABAA-dependent synaptic activity in rat striatal cholinergic interneurons. European Journal of Neuroscience, 2003, 17, 174-178.	2.6	11
462	Na + /Ca 2+ Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area. Stroke, 2007, 38, 1614-1620.	2.0	11
463	Occipital pseudoaneurysm as a complication of extension channel placement for DBS in Parkinson's disease. Movement Disorders, 2007, 22, 1834-1836.	3.9	11
464	Subclinical vestibular dysfunction in migraineurs without vertigo: A Clinical study. Acta Neurologica Scandinavica, 2018, 138, 270-277.	2.1	11
465	Dopamine drives bingeâ€like consumption of a palatable food in experimental Parkinsonism. Movement Disorders, 2019, 34, 821-831.	3.9	11
466	Reperfusion strategies in stroke due to isolated cervical internal carotid artery occlusion: systematic review and treatment comparison. Neurological Sciences, 2021, 42, 2301-2308.	1.9	11
467	Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia. European Journal of Neurology, 2022, 29, 564-572.	3.3	11
468	Lâ€3,4â€dihydroxyphenylalanineâ€induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?. Annals of Neurology, 2010, 68, 578-580.	5.3	10

#	Article	IF	Citations
469	Brain's traffic lights. Nature, 2010, 466, 449-449.	27.8	10
470	Levodopa-induced breathing, cognitive and behavioral changes in Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 2296-2299.	3.6	10
471	Migraine-specific quality of life questionnaire and relapse of medication overuse headache. BMC Neurology, 2015, 15, 85.	1.8	10
472	Diagnostic utility of CSF Î±-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. BMJ Open, 2016, 6, e011113.	1.9	10
473	Different synaptic stimulation patterns influence the local androgenic and estrogenic neurosteroid availability triggering hippocampal synaptic plasticity in the male rat. European Journal of Neuroscience, 2017, 45, 499-509.	2.6	10
474	Liverpool Adverse Events Profile: Italian validation and predictive value for dropout from antiepileptic treatment in people with epilepsy. Epilepsy and Behavior, 2018, 81, 111-114.	1.7	10
475	Levodopa-responsive breathing discomfort in Parkinsonâ€™s disease patients. Journal of Neural Transmission, 2018, 125, 1033-1036.	2.8	10
476	Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease. Journal of Neuroscience Research, 2019, 97, 1655-1664.	2.9	10
477	Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. Neurological Sciences, 2020, 41, 2819-2824.	1.9	10
478	Effect of the COVID-19 pandemic and the lockdown measures on the local stroke network. Neurological Sciences, 2021, 42, 1237-1245.	1.9	10
479	Transcranial Magnetic Stimulation Exerts â€œRejuvenationâ€•Effects on Corticostriatal Synapses after Partial Dopamine Depletion. Movement Disorders, 2021, 36, 2254-2263.	3.9	10
480	Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: a Single-Centre Experience. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 339-343.	0.9	10
481	Engagement of Rat Striatal Neurons by Cortical Epileptiform Activity Investigated With Paired Recordings. Journal of Neurophysiology, 2004, 92, 2725-2737.	1.8	9
482	l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via Î²-adrenergic receptors. Experimental Neurology, 2014, 261, 377-385.	4.1	9
483	Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm. Neurological Sciences, 2019, 40, 1887-1892.	1.9	9
484	Characterization of a Barium-sensitive Outward Current following Glutamate Application on Rat Midbrain Dopaminergic Cells. European Journal of Neuroscience, 1996, 8, 1780-1786.	2.6	8
485	Hypoxic and hypoglycaemic changes of intracellular pH in cerebral cortical pyramidal neurones. NeuroReport, 1998, 9, 1447-1450.	1.2	8
486	Application of ICHD 2nd edition criteria for primary headaches with the aid of a computerised, structured medical record for the specialist. Journal of Headache and Pain, 2005, 6, 205-210.	6.0	8

#	Article	IF	Citations
487	Multiple Cranial Nerve Palsies in a Patient with Internal Carotid Artery Dissection. European Neurology, 2007, 58, 125-127.	1.4	8
488	Acute dystonia induced by the combination of midodrine and perphenazine. Journal of Neurology, 2008, 255, 767-768.	3.6	8
489	Infliximab monotherapy for neuro-BehÃ§et's disease: A case report. Journal of the Neurological Sciences, 2014, 347, 389-390.	0.6	8
490	The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up. Neurological Sciences, 2019, 40, 2147-2153.	1.9	8
491	Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. Cephalalgia, 2019, 39, 1333-1338.	3.9	8
492	Neurology and the COVID-19 emergency. Neurological Sciences, 2020, 41, 1343-1344.	1.9	8
493	Stroke integrated care pathway during COVID-19 pandemic. Neurological Sciences, 2020, 41, 1673-1675.	1.9	8
494	Effects of safinamide on the glutamatergic striatal network in experimental Parkinsonâ€™s disease. Neuropharmacology, 2020, 170, 108024.	4.1	8
495	CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. Neurobiology of Disease, 2021, 158, 105473.	4.4	8
496	Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease. Cell Death Discovery, 2021, 7, 295.	4.7	8
497	A real-time integrated framework to support clinical decision making for covid-19 patients. Computer Methods and Programs in Biomedicine, 2022, 217, 106655.	4.7	8
498	Morphological and functional study of dwarf neurons in the rat striatum. European Journal of Neuroscience, 1998, 10, 3575-3583.	2.6	7
499	Impairment of mitochondrial metabolism differentially affects striatal neuronal subtypes. NeuroReport, 2002, 13, 641-644.	1.2	7
500	Deficits of glutamate transmission in the striatum of experimental hemiballism. Neuroscience, 2006, 143, 213-221.	2.3	7
501	Application of the ICHD-II Criteria to the Diagnosis of Primary Chronic Headaches Via a Computerized Structured Record. Headache, 2007, 47, 38-44.	3.9	7
502	Association Between Migraine and Headache Attributed to Stroke: A Caseâ€“Control Study. Headache, 2008, 48, 1468-1475.	3.9	7
503	Migraine with aura in the locker room: three case reports. Journal of Headache and Pain, 2012, 13, 91-93.	6.0	7
504	HDAC3 role in medication consumption in medication overuse headache patients: a pilot study. Human Genomics, 2015, 9, 30.	2.9	7

#	Article	IF	Citations
505	The changing tree in Parkinson's disease. Nature Neuroscience, 2015, 18, 1196-1198.	14.8	7
506	Early management of patients with medicationâ€overuse headache: results from a multicentre clinical study. European Journal of Neurology, 2018, 25, 1027-1033.	3.3	7
507	Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature. International Journal of Molecular Sciences, 2018, 19, 345.	4.1	7
508	A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB. Journal of Headache and Pain, 2020, 21, 124.	6.0	7
509	Long-term potentiation and memory processes in the psychological works of Sigmund Freud and in the formation of neuropsychiatric symptoms. Neuroscience, 2005, 130, 559-565.	2.3	6
510	Tiagabine and vigabatrin reduce the severity of NMDA-induced excitotoxicity in chick retina. Experimental Brain Research, 2006, 171, 511-515.	1.5	6
511	Neuroacanthocytosis associated with a defect of the 4.1R membrane protein. BMC Neurology, 2007, 7, 4.	1.8	6
512	A nurse-led model increases quality of care in Parkinson disease. Neurology, 2019, 92, 739-740.	1.1	6
513	Striatal spreading depolarization: Possible implication in levodopaâ€induced dyskineticâ€like behavior. Movement Disorders, 2019, 34, 832-844.	3.9	6
514	COVID-19 and stroke: from the cases to the causes. Reviews in the Neurosciences, 2021, 32, 659-669.	2.9	6
515	Extradural Motor Cortex Stimulation in Parkinsonâ€™s Disease: Long-Term Clinical Outcome. Brain Sciences, 2021, 11, 416.	2.3	6
516	Cognitive Decline Risk Stratification in People with Late-Onset Epilepsy of Unknown Etiology: An Electroencephalographic Connectivity and Graph Theory Pilot Study. Journal of Alzheimer's Disease, 2022, 88, 893-901.	2.6	6
517	Actions of Glycine on Non-dopaminergic Neurons of the Rat Substantia Nigra. European Journal of Neuroscience, 1995, 7, 2351-2354.	2.6	5
518	Electrophysiology of dopamine D-1 receptors in the basal ganglia: Old facts and new perspectives. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 779-793.	4.8	5
519	Hyperhomocysteinemia and retinal vascular changes in patients with epilepsy. Epilepsy Research, 2008, 81, 86-89.	1.6	5
520	Direct and indirect pathways in levodopaâ€induced dyskinesia: A more complex matter than a network imbalance. Movement Disorders, 2010, 25, 1527-1529.	3.9	5
521	Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. Journal of Headache and Pain, 2014, 15, 88.	6.0	5
522	Switching on the lights of dyskinesia: Perspectives and limits of the optogenetic approaches. Movement Disorders, 2017, 32, 485-486.	3.9	5

#	Article	IF	Citations
523	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. Multiple Sclerosis and Related Disorders, 2017, 17, 217-219.	2.0	5
524	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. Journal of Neurology, 2018, 265, 522-529.	3.6	5
525	Extradural Motor Cortex Stimulation might improve episodic and working memory in patients with Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 26.	5.3	5
526	Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinsonâ€™s Disease: Pulsatile versus Continuous Dopaminergic Stimulation. Journal of Parkinson's Disease, 2020, 10, 927-934.	2.8	5
527	Small-expanded allele spinocerebellar ataxia 17: imaging and phenotypic variability. Neurological Sciences, 2021, 42, 4309-4315.	1.9	5
528	Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. International Clinical Psychopharmacology, 2022, 37, 21-24.	1.7	5
529	Myostatin depletion: A therapy for Ehlersâ€Danlos syndrome?. Annals of Neurology, 2010, 67, 147-148.	5.3	4
530	Vomiting due to intravenous levetiracetam in a case of Creutzfeldtâ€"Jakob disease. Epilepsy and Behavior, 2010, 17, 133.	1.7	4
531	Prenatal stress and hippocampal BDNF expression: a fading imperative. Journal of Physiology, 2012, 590, 1309-1310.	2.9	4
532	Biomarker time out. Multiple Sclerosis Journal, 2014, 20, 1560-1563.	3.0	4
533	<scp>B</scp>iomarkers in <scp>P</scp>arkinson's disease: <scp>F</scp>rom pathophysiology to early diagnosis. Movement Disorders, 2016, 31, 769-770.	3.9	4
534	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. European Neurology, 2016, 76, 62-68.	1.4	4
535	Homer1b/c clustering is impaired in Phelan-McDermid Syndrome iPSCs derived neurons. Molecular Psychiatry, 2017, 22, 637-637.	7.9	4
536	Movement disorders in 2016: from genes to phenotypes. Lancet Neurology, The, 2017, 16, 9-10.	10.2	4
537	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinsonâ€™s disease: protocol for a systematic review and individual participant data meta-analysis. BMJ Open, 2017, 7, e018177.	1.9	4
538	Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. Journal of Neurology, 2019, 266, 2273-2276.	3.6	4
539	Defining the disease course of TNFÎ± blockers-associated Multiple Sclerosis. Journal of Neuroimmunology, 2021, 353, 577525.	2.3	4
540	Connectivity modulations induced by reach&grasp movements: a multidimensional approach. Scientific Reports, 2021, 11, 23097.	3.3	4

#	Article	IF	Citations
541	Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 167-184.	1.8	4
542	Alpha-synuclein and cortico-striatal plasticity in animal models of Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 153-166.	1.8	4
543	Adrenomyeloneuropathy partially responsive to steroid pulse therapy. Neurological Sciences, 2002, 23, 141-142.	1.9	3
544	Synaptic plasticity in the basal ganglia as a cellular model for spatial cognition and neurological disorders. Cognitive Processing, 2006, 7, 1-1.	1.4	3
545	Teaching Neuro <i>Images</i> : Acute tetraparesis. Neurology, 2009, 73, e58.	1.1	3
546	A young patient with type C multiple system atrophy and hereditary hemochromatosis. Journal of Neurology, 2010, 257, 294-295.	3.6	3
547	Seizure aggravation caused by antiepileptic drugs in a patient with muscleâ€“eyeâ€“brain disease. Epilepsy and Behavior, 2010, 19, 666-668.	1.7	3
548	Rhes-mTORC1 interaction: A new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia?. Movement Disorders, 2012, 27, 815-815.	3.9	3
549	A pathophysiological link between dystonia, striatal interneurons and neuropeptide Y. Brain, 2013, 136, 1341-1344.	7.6	3
550	Scientific research of Italian neurologists from 2008 to 2011. Neurological Sciences, 2014, 35, 437-442.	1.9	3
551	Drug-induced Creutzfeldt-Jakob disease-like syndrome: early CSF analysis as useful tool for differential diagnosis. BMJ Case Reports, 2018, 11, e224314.	0.5	3
552	Maternal stress programs accelerated aging of the basal ganglia motor system in offspring. Neurobiology of Stress, 2020, 13, 100265.	4.0	3
553	CACNA1A-p.Thr501Met mutation associated with familial hemiplegic migraine: a family report. Journal of Headache and Pain, 2021, 22, 85.	6.0	3
554	Ixekizumab exposure associated with myelitis: A case report and a literature review. Journal of Neuroimmunology, 2021, 361, 577726.	2.3	3
555	Serotonin drives striatal synaptic plasticity in a sex-related manner. Neurobiology of Disease, 2021, 158, 105448.	4.4	3
556	Long-Term Changes of Corticostriatal Synaptic Transmission: Possible Implication for Motor Memory. , 1995, , 89-103.		3
557	Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases. Frontiers in Neurology, 2021, 12, 800524.	2.4	3
558	Clinical and genetic characteristics of lateâ€onset Huntington's disease in a large European cohort. European Journal of Neurology, 2022, 29, 1940-1951.	3.3	3

#	Article	IF	Citations
559	Long-term changes of synaptic transmission: A topic of long-term interest. Behavioral and Brain Sciences, 1996, 19, 439-440.	0.7	2
560	Prolactin Response to Bromocriptine in Flunarizine-Treated Migrainous Women. Clinical Neuropharmacology, 1997, 20, 234-238.	0.7	2
561	Rhes, a key element of selective neuronal vulnerability in Huntington's disease: A striatalâ€specific license to kill during energy metabolism failure. Movement Disorders, 2013, 28, 735-735.	3.9	2
562	â€œLazyâ€•nigrostriatal synapses in the heterozygous PINK1 mouse model of familial Parkinson's disease. Movement Disorders, 2014, 29, 11-14.	3.9	2
563	Migraine and epilepsy: what value today?. Journal of Headache and Pain, 2015, 16, A44.	6.0	2
564	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. Journal of Neurology, 2016, 263, 1449-1451.	3.6	2
565	Levetiracetam-responsive belly dancerâ€™s syndrome in a case of progressive supranuclear palsy. Acta Neurologica Belgica, 2021, 121, 765-766.	1.1	2
566	Mechanical thrombectomy in patients with stroke due to large vessel occlusion in the anterior circulation and low scale score. Journal of Integrative Neuroscience, 2021, 20, 645.	1.7	2
567	Role of Favorable Perfusion Imaging in Predicting the Outcome of Patients with Acute Ischemic Stroke due to Large Vessel Occlusion Undergoing Effective Thrombectomy: A Single-Center Study. Cerebrovascular Diseases Extra, 2021, 11, 1-8.	1.5	2
568	Long-Term Shaping of Corticostriatal Synaptic Activity by Acute Fasting. International Journal of Molecular Sciences, 2021, 22, 1916.	4.1	2
569	Glutamate Receptors and Levodopa-Induced Dyskinesia. , 2014, , 229-243.		2
570	Giant Basilar Apex Aneurysm Presenting as Bilateral Thalamic Compression with Neuropsychological Disorders. European Neurology, 2006, 56, 57-58.	1.4	1
571	Nerve growth factor and brain-derived neurotrophic factor: potential targets for migraine treatment?. Expert Opinion on Therapeutic Patents, 2008, 18, 705-721.	5.0	1
572	Biological substrates of migraine. Journal of Headache and Pain, 2015, 16, A19.	6.0	1
573	Morning akinesia in Parkinson's disease: challenges and solutions. Journal of Parkinsonism and Restless Legs Syndrome, 2016, , 57.	0.8	1
574	Regulation of Corticostriatal Synaptic Plasticity in Physiological and Pathological Conditions. Handbook of Behavioral Neuroscience, 2016, 24, 459-476.	0.7	1
575	Environmental Enrichment Repairs Structural and Functional Plasticity in the Hippocampus. , 2017, , 55-77.		1
576	The Madwoman: a portrait of a choreic woman?. Lancet Neurology, The, 2019, 18, 233.	10.2	1

#	Article	IF	Citations
577	The contribution of the Italian residents in neurology to the COVID-19 crisis: admirable generosity but neurological training remains their priority. Neurological Sciences, 2021, 42, 4425-4431.	1.9	1
578	Basic Electrophysiology and Possible New Therapeutic Approaches to Movement Disorders. Advances in Behavioral Biology, 1994, , 229-237.	0.2	1
579	Delirium in acute stroke: A single centre, prospective, cross-sectional, cohort study. Journal of the Neurological Sciences, 2021, 429, 117655.	0.6	1
580	Cognitive decline risk stratification in people with late-onset epilepsy of unknown etiology: An electroencephalographic connectivity and graph theory pilot study. Journal of the Neurological Sciences, 2021, 429, 117686.	0.6	1
581	Glutamate Transmission in the Pathogenesis of Parkinsonâ€™s Disease. , 2004, , 229-242.		1
582	STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, .	5.3	1
583	1.4 INCREASED AORTIC STIFFNESS IN YOUNG SUBJECTS WITH MIGRAINE. Artery Research, 2009, 3, 151.	0.6	0
584	Lysosomal enzyme activities in human brain. Journal of Biotechnology, 2014, 185, S7.	3.8	0
585	P066. Migraine with aura in the locker room: 4 case reports. Journal of Headache and Pain, 2015, 16, A169.	6.0	0
586	O064. Antiepileptic drugs in migraine and epilepsy disorders: who is at increased risk of adverse events?. Journal of Headache and Pain, 2015, 16, A69.	6.0	0
587	Epilepsy, headache, and chronic pain. , 2019, , 187-205.		0
588	Teaching Images in Headache: Thrombosis of Posterior Communicating Artery Aneurysm. Headache, 2019, 59, 630-631.	3.9	0
589	Giacomo Balla: A Painter in the Context of Neuroscience. Neuroscientist, 2020, , 107385842097638.	3.5	0
590	CACNA1A-P.THR501MET mutation associated with familial hemiplegic migraine: A family report. Journal of the Neurological Sciences, 2021, 429, 119276.	0.6	0
591	CSF CXCL13 and chitinase 3-like-1 concentrations predict disease course in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2021, 429, 118114.	0.6	0
592	Cognitive decline in late-onset epilepsy of undefined etiology: A longitudinal cohort study. Journal of the Neurological Sciences, 2021, 429, 117709.	0.6	0
593	Interleukin-17 axis in the modulation of cortical and subcortical synaptic plasticity across disease stages in experimental multiple sclerosis. Journal of the Neurological Sciences, 2021, 429, 117746.	0.6	0
594	Theory of mind: A clue to functional movement disorders diagnosis. Journal of the Neurological Sciences, 2021, 429, 117681.	0.6	0

#	Article	IF	Citations
595	Lexical-semantic system disruption correlation with Alzheimer's pathophysiological processes. Journal of the Neurological Sciences, 2021, 429, 119011.	0.6	0
596	Motor and neurophysiological features of sleep in Huntington disease: A single-center, prospective, cross-sectional, cohort study. Journal of the Neurological Sciences, 2021, 429, 117833.	0.6	0
597	Dopamine-Dependent Long-Term Potentiation Induced by 3-Nitropropionic Acid in Striatal Medium Spiny Neurons. Advances in Behavioral Biology, 2002, , 187-190.	0.2	0
598	Cellular Actions of Dopamine. Handbook of Experimental Pharmacology, 2002, , 299-319.	1.8	0
599	Short and Long Term Modulation of Synaptic Activity in Striatal Cholinergic Interneurons. , 2005, , 91-97.		0
600	Basi neurobiologiche dei deficit cognitivi nella malattia di Parkinson. , 2009, , 99-113.		0
601	Regulation of Corticostriatal Synaptic Plasticity in Physiological and Pathological Conditions. Handbook of Behavioral Neuroscience, 2010, , 219-229.	0.7	0
602	Medication Overuse Headache: Causes, Consequences, and Treatment. , 2012, , 351-362.		0